Pulmonary arterial hypertension (PAH), defined as a mean pulmonary artery pressure (PAPm) ≥ 25 mm Hg with a pulmonary capillary wedge pressure ≤ 15 mm Hg measured by cardiac catheterization ...

PADN has emerged as a promising treatment ... "Pulmonary artery denervation has become a promising therapeutic intervention in the management of pulmonary hypertension,” commented Dr. Jenkins.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Pulmonary arterial hypertension (PAH ... has been approved for treatment since September 2024. Its effectiveness was previously investigated in stable patients in the international STELLAR ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

In 2021, a greater number of global pulmonary arterial hypertension cases occurred in females vs. males, and disease ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial. Among 172 ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...